Back to Top Skip to main content Skip to sub-navigation

Special Report: Early Use of ICD-10-CM Code “U07.1, COVID-19” to Identify 2019 Novel Coronavirus Cases in Military Health System Administrative Data

Image of Hospital ship USNS Comfort returns to its homeport after treating patients in New York and New Jersey in support of the COVID-19 pandemic. Click to open a larger version of the image. The hospital ship USNS Comfort returns to its homeport after treating patients in New York and New Jersey in support of the COVID-19 pandemic. (U.S. Navy photo by Mass Communication Specialist 1st Class Joshua D. Sheppard/Releaseds)

Recommended Content:

Medical Surveillance Monthly Report

WHAT ARE THE NEW FINDINGS?

This study identified possible cases of COVID-19 in distinct data record systems that included laboratory tests for the coronavirus, DRSi reports of cases, and records of healthcare encounters that included the new ICD-10 code U07.1 for the disease. Examination of 150 encounter records for individuals who were not identified in the laboratory or DRSi records revealed that 69% had confirmatory lab results in separate records or met clinical criteria for a case of COVID-19.

WHAT IS THE IMPACT ON READINESS AND FORCE HEALTH PROTECTION?

The findings provide evidence that use of the new ICD-10 diagnostic code for COVID-19 is occurring more frequently since its introduction. Search of encounter records for this code will augment the other methods of performing surveillance for this disease. Such enhanced surveillance will enable actions to prevent and control the current COVID-19 epidemic, which threatens the health of the force.

ABSTRACT

This report describes early exploratory analysis of ICD-10-CM code U07.1 (2019-nCoV acute respiratory disease [COVID-19]) to assess the use of administrative data for case ascertainment, syndromic surveillance, and future epidemiological studies. Out of the 2,950 possible COVID-19 cases identified between 1 April 2020 and 4 May 2020, 600 (20.3%) were detected in the Defense Medical Surveillance System (DMSS) and not in the Disease Reporting System internet (DRSi) or in Health Level 7 laboratory data from the Composite Health Care System. Among the 150 out of 600 cases identified exclusively in the DMSS and selected for Armed Forces Health Longitudinal Technology Application (AHLTA) review, 16 (10.7%) had a certified positive lab result in AHLTA, 17 (11.3%) met Council of State and Territorial Epidemiologists (CSTE) criteria for a probable case, 46 (30.7%) were not cases based on CSTE criteria, and 71 (47.3%) had evidence of a positive lab result from an outside source. Lack of full capture of lab results may continue to be a challenge as the variety of available tests expands. Administrative data may provide an important stopgap measure for detecting lab positive cases, pending incorporation of new COVID-19 tests and standardization of test and result nomenclature.

BACKGROUND

On 30 January 2020, the World Health Organization (WHO) declared that an outbreak of disease named 2019-nCoV, later named coronavirus disease 2019 (COVID-19), was a Public Health Emergency of International Concern.1 One day later, on 31 January 2020, WHO convened an emergency meeting of the WHO Family of International Classifications Network and Statistics Advisory Committee to create a specific International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) code for the new coronavirus: U07.1, 2019-nCoV acute respiratory disease.2 On 20 February 2020, the U.S. Centers for Disease Control and Prevention (CDC) National Center for Health Statistics announced that it would implement the new ICD-10-CM code on 1 October 2020.3

Following the WHO declaration that the novel coronavirus was a global pandemic (11 March 2020) 4 and the President’s activation of the Stafford Act (13 March 2020),5 CDC, under sections 201 and 301 of the U.S. National Emergencies Act, announced that the effective date of the new diagnosis code would be moved from 1 October 2020 to 1 April 2020.6

The Military Health System (MHS) made ICD-10-CM code U07.1 available for selection by appointers and other administrative personnel in MHS GENESIS and the Composite Health Care System (CHCS) in early April 2020. Soon thereafter, the code became available to medical providers utilizing MHS GENESIS and the Armed Forces Health Longitudinal Technology Application (AHLTA) to document the diagnosis of COVID-19. Since the end of April 2020, epidemiologists and analysts have been able to query administrative databases including the MHS Data Repository (MDR), MHS Mart (M2), the CHCS, and the Defense Medical Surveillance System (DMSS) using the new code.

The Armed Forces Health Surveillance Branch (AFHSB) creates a daily master positive list of COVID-19 cases by combining data from the Disease Reporting System internet (DRSi) and Health Level 7 (HL7)-formatted laboratory data (HL7 data) extracted from the CHCS and MHS GENESIS by the Navy and Marine Corps Public Health Center. The availability of the specific ICD-10-CM code U07.1 provides a new source of data for identification of possible cases of COVID-19 using the electronic health record (EHR). It also provides an opportunity to create a COVID-19-like illnesses (CLI) case definition for syndromic surveillance modeled after influenza-like illness (ILI) surveillance. This report documents early exploratory analysis of ICD-10-CM code U07.1 to assess the potential use of administrative data for case ascertainment and use of the code for syndromic surveillance and future epidemiological studies (Figure 1).

METHODS

On 4 May 2020, the DMSS was searched for all patient encounters that contained ICD-10-CM code U07.1 in any diagnostic position. This list of possible COVID-19 cases was compared to the master positive list (cases identified based on positive test for severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2, the virus that causes COVID-19, and/or those who were reported as cases in the DRSi between 1 April 2020 and 4 May 2020). A convenience sample (25%) of these cases was selected for record review in AHLTA. Within AHLTA, for each case, information contained in the lab, radiology, previous encounters, Joint Legacy Viewer, and Health Artifact and Image Management Solution sections was reviewed by a licensed medical provider using a standardized Excel spreadsheet and systematic AHLTA review process. Cases in the DMSS-only subset were categorized as probable, confirmed, or determined not to be a case based on the guidelines established by the Council of State and Territorial Epidemiologists (CSTE)7 (Table).

On 8 May 2020, a 10-day “look-back” was performed. A separate DMSS list (U07.1 ICD-10-CM code list) from 28 April 2020 was compared with the master positive list (DRSi and/or HL7 data list) from 8 May 2020 to determine the number of DMSS U07.1 coded cases that were subsequently identified on the master positive list and, therefore, would have been captured without the use of administrative data.

Note that MHS GENESIS medical encounters did not become available in the DMSS until after this analysis was performed. While laboratory results from MHS GENESIS sites were included in this analysis, MHS GENESIS medical encounters were not included here.

RESULTS

There were 2,350 individuals captured on the master positive list (cases identified based on positive lab test and/or those who were reported as cases in the DRSi between 1 April 2020 and 4 May 2020) and 865 individuals who were identified as having an encounter for COVID-19 (ICD-10-CM code U07.1) during the same time period. Among the 2,950 total individuals identified, 2,085 were exclusively on the master positive list, 600 were exclusively on the ICD-10-CM U07.1 diagnosis code list, and 265 were on both (Figure 2).

Among the 150 out of 600 cases identified exclusively in the DMSS and selected for AHLTA review, 16 (10.7%) had a certified positive lab result in the laboratory section of AHLTA, 17 (11.3%) met CSTE criteria for a probable case, 46 (30.7%) were not cases based on CSTE criteria, and 71 (47.3%) had evidence of a positive lab result from an outside source (Figure 3). Among the 46 cases that were determined not to be cases, 26 (56.5%) were seen for screening (e.g., pre-deployment screening rather than COVID-19 itself).

On 28 April 2020, there were 64 individuals on the U07.1 code-only list. By 8 May 2020, 7 (10.9%) had made it onto the master positive list (3 cases were represented exclusively in the DRSi, 2 cases were represented exclusively in HL7 data, and 2 were represented in both data sources) (Figure 4).

EDITORIAL COMMENT

Availability of ICD-10-CM code U07.1 in administrative data is an important new development in COVID-19 surveillance. Given that 600 out of the 2,950 possible cases (20.3%) reviewed here were detected in administrative data and not in DRSi or HL7 data, addition of encounter data appears to be important to ensuring complete case capture moving forward.

Among the 150 cases selected for AHLTA review, 16 cases (10.7%) identified in encounter data were found to have a military treatment facility (MTF)-certified lab result in the AHLTA labs section but were not identified in the DRSi or the HL7 data and, therefore, were not represented on the master positive list. The 10-day look-back revealed that 7 cases were subsequently identified and entered into the master positive list, 2 of which were found exclusively in HL7 data, 3 of which were exclusively in DRSi data, and 2 of which were in both. While some of the remaining lab cases may eventually make it into the HL7 data, 2 of the missed lab results were from early April (2 April 2020 and 3 April 2020), suggesting that they might escape recognition altogether. Given that SARS-CoV-2 laboratory test names and results are not standardized in CHCS or HL7 data, this is understandable. While capture of these cases will likely improve as naming conventions are standardized and algorithms aimed at capturing COVID-19 test results evolve, lack of full capture of lab results may continue to be a challenge as the variety of tests available continues to expand. Administrative data may provide an important stopgap measure for detecting lab positive cases, pending incorporation of new COVID-19 tests and standardization of test and result nomenclature.

The CSTE definitions for confirmed and probable cases of COVID-19 are provided in the Table.7 Among the 150 cases reviewed, there were 17 probable cases of COVID-19: 2 had presumptive positive lab test results and met clinical or epidemiologic criteria; 15 met clinical and epidemiologic criteria. Among the 150 cases reviewed, 8 patients were hospitalized and 11 had chest imaging (x-ray or computed tomography [CT] scan) consistent with COVID-19.

It could be argued that cases with both clinical and radiographic evidence of COVID-19 should be categorized as cases. This approach is substantiated by Ai and colleagues, who performed serial analyses of reverse transcriptase polymerase chain reaction (RT-PCR) and CT scans and found that, using RT-PCR as a reference, the sensitivity of chest imaging for COVID-19 was 97%.8 Use of radiographic criteria for case identification would increase the proportion of individuals identified as cases in the EHR from 87 total cases (58.0%) to 98 total cases (65.3%). In this analysis, the CSTE case definition was applied to remain consistent with current public health practice.

Among the 150 AHLTA cases reviewed, the largest group of patients, 71 (47.3%), received lab testing at an outside facility, such as an urgent care center, hospital, or state health department, along with a documented encounter (most frequently a telephone consult) at an MTF. Lab results were sometimes scanned into the record and the test location was documented in 51/71 cases (71.8%). Given that these tests were not entered into the CHCS, they had no opportunity to be detected in HL7 data. The DRSi, a passive surveillance system with known limitations related to personnel, training, and accessibility, also did not identify these cases.9 This again demonstrates the value of using administrative data for comprehensive case capture.

Outsourced medical encounter data are available in MHS systems (e.g., the MDR, M2, and DMSS) after an encounter is billed. The billing process can take weeks to months, especially if a patient is hospitalized for a prolonged period of time. In the current analysis, many outsourced encounters not reported in the DRSi were detected because they were associated with a telephone consult undertaken for case management or public health purposes. Coding of the telephone consultations in the EHR allowed identification of cases at the time of illness rather than weeks later, as would be the case had these consults not been recorded. This finding suggests that the EHR may be an important adjunct to the DRSi for identification of cases requiring contact tracing.

The current analysis included 46 individuals (30.7%) who did not meet CSTE criteria for COVID-19 but who were, nonetheless, documented as having COVID-19, based solely on the ICD-10-CM U07.1 code. This misclassification was due to the use of ICD-10-CM code U07.1 for documentation of pre-deployment screening among asymptomatic service members rather than the appropriate screening code (ICD-10-CM code Z11.59, encounter for screening for other viral disease) in 56.5% of the 46 cases. Given the prospect of increased screening among recruits and other large military groups, continued improper use of this code for screening purposes could lead to significant misclassification of cases in the future, undermining the value of ICD-10-CM code U07.1 for case identification and development of a case definition for CLI syndromic surveillance. “ICD-10-CM Official Coding and Reporting Guidelines, 1 April 2020 through 30 September 2020” advises against assigning ICD-10-CM code U07.1 to unconfirmed cases, including suspected, possible, probable, and inconclusive cases. It further directs the use of ICD-10-CM code Z11.59 for asymptomatic screening.10 The 13 May 2020 Defense Health Agency memorandum “Standardizing COVID-19 Laboratory Orders to Distinguish Among Diagnostic, Screening and Surveillance Testing Purposes” elaborates on these recommendations.11 Wide dissemination of these guidelines is warranted.

This review attempted to rapidly evaluate early use of ICD-10-CM code U07.1 in order to assure the accuracy of AFHSB’s master positive list and to develop of a reliable CLI case definition. In the interest of timeliness, information in the medical record was extracted by a single individual rather than multiple providers, as would be required in a formal case series or systematic review. In addition, a convenience sample (the first 150 out of 600 cases) rather than a randomly selected sample of AHLTA cases was designated for review. These factors limit the validity and generalizability of the analysis. This analysis is further limited by the small number of cases reviewed and the fact that it was performed soon after adoption of ICD-10-CM code U07.1. Recognizing these limitations, it appears that use of ICD-10-CM code U07.1 to query administrative databases allows identification of cases that would not otherwise be detected using DRSi and HL7 data alone. Advocacy for use of administrative data to identify cases is tempered somewhat not only by the potential for misclassification but also by the manpower required to review the electronic medical record and apply CSTE guidelines for appropriate case classification. Lipstitch and colleagues astutely recognized that “case-based surveillance places exponentially increasing burdens on public health systems” and highlighted the importance of transitioning from case-based surveillance to automated syndromic surveillance as pandemics evolve.12

The use of ICD-10-CM code U07.1 for syndromic surveillance and future epidemiological studies warrants continued exploration, especially given use of this code for screening purposes and resultant misclassification. Continued addition of codes such as ICD-10-CM U07.2 COVID-19, virus not detected13 and refinement of codes sets used for syndromic surveillance will provide greater understanding of how COVID-19 is affecting military members and military-associated populations and ensure the integrity of future epidemiological studies related to COVID-19.

REFERENCES

1. World Health Organization. Coronavirus disease (COVID-19) outbreak. https://www.who.int/westernpacific/emergencies/covid-19. Accessed 1 May 2020.

2. World Health Organization. Emergency use ICD codes for COVID-19 disease outbreak https://www.who.int/classifications/icd/covid19/en/. Accessed 1 May 2020.

3. Centers for Disease Control and Prevention. ICD-10-CM Official Coding Guidelines-Supplement. Coding encounters related to COVID-19 coronavirus outbreak. Effective: February 20, 2020. https://www.cdc.gov/nchs/data/icd/ICD-10-CMOfficial-Coding-Gudance-Interim-Advice-coronavirus-feb-20-2020.pdf. Accessed 1 May 2020.

4. World Health Organization. Rolling updates on coronavirus disease (COVID-19). https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen. Accessed 2 May 2020.

5. United States White House. Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak. https://www.whitehouse.gov/presidential-actions/proclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak/. Accessed 3 May 2020.

6. Centers for Disease Control and Prevention. New ICD-10-CM code for the 2019 novel coronavirus (COVID-19), April 1, 2020. Effective: March 18, 2020. https://www.cdc.gov/nchs/data/icd/Announcement-New-ICD-code-for-coronavirus-3-18-2020.pdf. Accessed 1 May 2020.

7. Council of State and Territorial Epidemiologists. Standardized surveillance case definition and national notification for 2019 novel coronavirus disease (COVID-19). 4 April 2020.

8. Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 Cases. Radiology. 2020;26:200642.

9. Ambrose JF, Kebisek JK, Gibson KJ, White DV, O’Donnell FL. Gaps in reportable medical event surveillance across the Department of the Army and recommended training tools to improve surveillance practices. MSMR. 2019;26(8):17–21.

10. Centers for Disease Control and Prevention. ICD-10-CM Official Coding and Reporting Guidelines April 1, 2020 through September 30, 2020. https://www.cdc.gov/nchs/data/icd/COVID-19-guidelines-final.pdf. Accessed 3 May 2020.

11. Department of Defense. Defense Health Agency. Memorandum. Standardizing COVID-19 Laboratory Orders to Distinguish Among Diagnostic, Screening, and Surveillance Testing Purposes. 13 May 2020.

12. Lipsitch M, Hayden FG, Cowling BJ, Leung GM. How to maintain surveillance for novel influenza A H1N1 when there are too many cases to count. Lancet. 2009;374(9696):1209–1211.

13. World Health Organization. Emergency use ICD codes for COVID-19 disease outbreak. https://www.who.int/classifications/icd/covid19/en/. Accessed 5 May 2020.

FIGURE 1. COVID-19 data sources and products

FIGURE 2. COVID-19 case identification using the master positive list and ICD-10-CM code U07.1, 1 April 2020–1 May 2020

FIGURE 3. Cases reviewed in AHLTA (150 cases out of 600 total)
FIGURE 4. Ten-day look-back for identification of cases that were initially not found but subsequently identified in DRSi and/or HL7 data

TABLE. CSTE standardized surveillance case definition for COVID-19

 

You also may be interested in...

Diagnosis of hepatitis C infection and cascade of care in the active component, U.S. Armed Forces, 2020

Article
2/1/2022
Navy Petty Officer 2nd Class Cecil Dorse, left, and Navy Petty Officer 3rd Class Janet Rosas test blood samples aboard the Military Sealift Command hospital ship USNS Comfort while the ship is in New York City in support of the nation’s COVID-19 response, April 6, 2020. Photo By: Navy Petty Officer 2nd Class Sara Eshleman

Hepatitis C virus (HCV) infection rates are rising in the U.S. despite widely available tools to identify and effectively treat nearly all of these cases. This cross-sectional study aimed to use laboratory data to evaluate the prevalence of HCV diagnoses among active component U.S. military service members.

Recommended Content:

Medical Surveillance Monthly Report

A new approach to categorization of ocular injury among U.S. Armed Forces

Article
2/1/2022
Air Force and Space Force Surgeon General Lt. Gen. Dorothy Hogg receives an eye exam from Air Force Reserve Maj. Leslie Wilderson at Joint Base Anacostia-Bolling, Washington, D.C., March 26, 2021. Photo By: Air Force Staff Sgt. Kayla White

Ocular injuries present an ongoing threat to readiness and retention of service members. This report describes a new approach to categorizing ocular injury using Military Health System data, the application of an algorithm to a dataset, and the verification of the results using an audit of clinical data.

Recommended Content:

Medical Surveillance Monthly Report

Surveillance snapshot: Health care burden attributable to osteoarthritis and spondylosis, active component, U.S. Armed Forces, 2016–2020

Article
2/1/2022
Air Force security forces trainees climb a hill during a 3-mile ruck march to commemorate National Police Week at Joint Base San Antonio, May 13, 2019. Photo By: Sarayuth Pinthong, Air Force

This snapshot summarizes the total numbers of inpatient and outpatient encounters with an OA or spondylosis diagnosis in the first diagnostic position and the total numbers of unique individuals affected by these conditions during the same 5-year surveillance period.

Recommended Content:

Medical Surveillance Monthly Report

Description of a COVID-19 Beta Variant Outbreak, Joint Base Lewis-McChord, WA, February–March 2021

Article
1/1/2022
U.S. Army Soldiers from 1-17th Infantry Battalion, 2nd Stryker Brigade, 2nd Infantry Division, clear an objective during the training exercise Bayonet Focus 19-02 at Yakima Training Center, Wash., May 6, 2019. Bayonet Focus is a training exercise designed to assess Soldiers’ ability to preform tasks and complete objectives under conditions experienced during combat situations. (U.S. Army photo by Spc. Angel Ruszkiewicz)

This report describes an outbreak of SARS-CoV-2, the causative agent of COVID-19, that peaked during 21–26 February 2021 and was tied to a single military training event. A total of 143 laboratory-confirmed cases were identified.

Recommended Content:

Medical Surveillance Monthly Report

COVID-19 and Depressive Symptoms Among Active Component U.S. Service Members, January 2019–July 2021

Article
1/1/2022
With the holiday season upon us, the cold, dark days that winter brings, and the social distancing and movement restrictions brought about by COVID-19, it’s not uncommon for people to feel depressed. (Photo by Erin Bolling)

This study examined the rates of depressive symptoms in active component U.S. service members prior to and during the COVID-19 pandemic and evaluated whether SARS-CoV-2 test results (positive or negative) were associated with self-reported depressive symptoms.

Recommended Content:

Medical Surveillance Monthly Report

Surveillance Snapshot: Lengths of Hospital Stays for Service Members Diagnosed with Sepsis, Active Component, U.S. Armed Forces, 2011–2020

Article
1/1/2022
The (left to right) Senior Airman Austin Shrewsbury, 88th Diagnostics and Therapeutic Squadron medical laboratory technician, works with student, Airman 1st Class Taylor Altman, 88th Diagnostics and Therapeutic Squadron medical laboratory technician, to identify bacteria of patient’s cultures inside the microbiology laboratory at Wright-Patterson Air Force Base medical center June 30, 2017.

Sepsis is a serious and life-threatening organ dysfunction caused by a dysregulated host response to infection. In the U.S., sepsis is a leading cause of in-hospital mortality and 1 of the most expensive conditions treated in U.S. hospitals.

Recommended Content:

Medical Surveillance Monthly Report

Incident COVID-19 Infections, Active and Reserve Components, Jan. 1, 2020–Aug. 31, 2021

Article
12/1/2021
U.S. Marines with Marine Rotational Force - Darwin receive a second COVID-19 test during quarantine on Royal Australian Air Force Base Darwin in Darwin, NT, Australia, June 12, 2020. The COVID-19 test was administered to each Marine after arriving from California. All Marines will be quarantined for 14 days and undergo an additional test before quarantine release. No Marines tested positive for COVID-19. The U.S. Marine Corps and Australian Defence Force service members are working together to ensure the safety of the local community. (U.S. Marine Corps photo by Lance Cpl. Natalie Greenwood)

Incident COVID-19 Infections, Active and Reserve Components, 1 January 2020–31 August 2021

Recommended Content:

Medical Surveillance Monthly Report

Surveillance Snapshot: Donovanosis Among Active Component Service Members, U.S. Armed Forces, 2011–2020

Article
12/1/2021
This photomicrograph of a tissue sample extracted from a lesion in the inguinal region of the female granuloma inguinale, or Donovanosis patient, depicted in PHIL 6431, revealed a white blood cell (WBC) that contained the pathognomonic finding of Donovan bodies, which were encapsulated, Gram-negative rods, representing the responsible bacterium Klebsiella granulomatis, formerly known as Calymmatobacterium granulomatis. Photo credit: CDC/ Susan Lindsley

Recommended Content:

Medical Surveillance Monthly Report

Update: Osteoarthritis and Spondylosis, Active Component, U.S. Armed Forces, 2016–2020

Article
12/1/2021
Osteoarthritis (OA) knee . film x-ray AP ( anterior - posterior ) and lateral view of knee show narrow joint space, osteophyte ( spur ), subchondral sclerosis, knee joint inflammation. Photo by: iStockPhoto

Osteoarthritis (OA), the most com­mon adult joint disease, is primarily a degenerative disorder of the entire joint organ, including the subchondral bone, synovium, and periarticular structures (e.g., tendons, ligaments, bursae). Spondylosis, often referred to as OA of the spine, is characterized by degenerative changes in the vertebral discs, joints, and vertebral bodies.

Recommended Content:

Medical Surveillance Monthly Report

Update: Plant Dermatitis Among Active Component Service Members, U.S. Armed Forces, 2010–2020

Article
11/1/2021
Poison ivy (Toxicodendron radicans)

Plant dermatitis is an allergic inflammatory skin reaction in response to the oils of poisonous plants. In the U.S., the most common dermatitis-causing plant genus is the Toxicodendron (formerly Rhus). Approximately 50%–75% of the U.S. adult population are susceptible to skin reactions upon exposure to Toxicodendron oil or oleoresin, called urushiol.

Recommended Content:

Medical Surveillance Monthly Report

Sepsis Hospitalizations Among Active Component Service Members, U.S. Armed Forces, 2011–2020

Article
11/1/2021
SAN DIEGO (Oct. 19, 2020) Hospital Corpsman 2nd Class Brittni Porter, a laboratory technician assigned to Naval Medical Center San Diego’s (NMCSD) microbiology laboratory, exams agar slides during a drug susceptibility tests Oct. 19. Drug susceptibility tests are conducted to see if a particular antibiotic will react with a patient’s sample on an agar slide. NMCSD’s mission is to prepare service members to deploy in support of operational forces, deliver high quality healthcare services and shape the future of military medicine through education, training and research. NMCSD employs more than 6,000 active duty military personnel, civilians, and contractors in Southern California to provide patients with world-class care anytime, anywhere. (U.S. Navy photo by Mass Communication Specialist 3rd Class Jake Greenberg)

Recommended Content:

Medical Surveillance Monthly Report

Brief Report: Prevalence of Hepatitis C Virus Infections in U.S. Air Force Basic Military Trainees Who Donated Blood, 2017–2020

Article
11/1/2021
U.S. Army Staff Sgt. Brandon Sousa, 424th Engineer Vertical Construction Company, donates blood to the 379th Expeditionary Medical Group’s Blood Support Center, Aug. 30, 2021, at Al Udeid Air Base, Qatar. The blood support center conducted a walking blood bank to collect blood from prescreened and cleared donors. The blood was sent downrange to support Afghanistan evacuation operations. The DoD is committed to supporting the U.S. State Department in the departure of U.S. and allied civilian personnel from Afghanistan, and to evacuate Afghan allies to safety. (U.S. Air Force photo by Senior Airman Kylie Barrow)

Recommended Content:

Medical Surveillance Monthly Report

Brief Report: The Challenge of Interpreting Repeated Positive Tests for SARS-CoV-2 Among Military Service Members, Fort Jackson, SC, 2020–2021

Article
10/1/2021
Gloved hand holding an example of a negative rapid test for the SARS-CoV-2 virus (COVID-19).

Recommended Content:

Medical Surveillance Monthly Report

Surveillance Snapshot: History of COVID-19 Vaccination Among Air Force Recruits Arriving at Basic Training, March 2–June 15, 2021

Article
10/1/2021
COVID-19 vaccine bottle and syringes

Recommended Content:

Medical Surveillance Monthly Report

Update: Cold Weather Injuries, Active and Reserve Components, U.S. Armed Forces, July 2016–June 2020

Article
10/1/2021
A student in the army participates in a cold-water immersion training

Recommended Content:

Medical Surveillance Monthly Report
<< < 1 2 3 4 5  ... > >> 
Showing results 1 - 15 Page 1 of 15

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.